What is Sofregen Medical?
Sofregen Medical Inc. operates at the intersection of advanced material science and clinical application, specializing in the development of purified silk protein biomaterials. The company's core value proposition lies in its ability to facilitate soft tissue regeneration, a capability exemplified by its Silk Voice Injectable Implant. By providing medical practitioners with high-performance tools for vocal fold medialization and other aesthetic procedures, Sofregen is effectively redefining the standards for surgical outcomes. Their focus on unlocking the biological potential of silk protein allows for superior biocompatibility and structural integrity, addressing unmet needs in the aesthetic medicine market. Through rigorous scientific inquiry and a focus on practitioner empowerment, the company has established a robust intellectual property foundation that supports its ongoing market expansion.
How much funding has Sofregen Medical raised?
Sofregen Medical has raised a total of $19.4M across 4 funding rounds:
Angel/Seed
$1.6M
Series A
$9.7M
Series B
$8M
Debt
$150K
Angel/Seed (2014): $1.6M, investors not publicly disclosed
Series A (2016): $9.7M led by Polaris Partners
Series B (2019): $8M supported by Anzu Partners
Debt (2020): $150K featuring PPP
Key Investors in Sofregen Medical
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise to foster innovation.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing significant assets to support founders in bringing innovative solutions to market.
Undisclosed Investors
What's next for Sofregen Medical?
With a history of consistent capital backing, Sofregen Medical is well-positioned to scale its commercial operations and deepen its clinical research pipeline. The recent influx of capital provides the necessary runway to accelerate the adoption of its flagship products while exploring new indications for its silk-based platform. As the company transitions into a more mature phase of its lifecycle, strategic priorities will likely include expanding its global distribution network and securing additional regulatory clearances for its biomaterial portfolio. By maintaining its focus on high-impact medical solutions, Sofregen is poised to capture significant market share within the competitive landscape of regenerative and aesthetic healthcare.
See full Sofregen Medical company page
